Agenus

Performance

About Agenus

Agenus is a biotechnology company focused on immuno-oncology, developing antibody-based therapies and combination approaches to expand the patient population benefiting from cancer immunotherapy. The company advances programs in oncology through its own pipelines and through partnerships, with manufacturing and clinical capabilities described across its US and European operations. Its portfolio includes next-generation CTLA-4 antibodies and other immuno-oncology therapeutics, plus subsidiaries involved in adoptive cell therapies and adjuvants/vaccines. Agenus emphasizes curb-to-curate development of curative therapies and access to investigational medicines for patients worldwide.